Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 1092-1093, 2008; 10.1373/clinchem.2007.102194
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zanglis, A.
Right arrow Articles by Baziotis, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zanglis, A.
Right arrow Articles by Baziotis, N.
(Clinical Chemistry. 2008;54:1092-1093.)
© 2008 American Association for Clinical Chemistry, Inc.

Letters to the Editor

Influence of L-Thyroxine Therapy on Parathyroid Hormone Concentrations

Adonios Zanglisa, Demetrios Andreopoulos and Nikolaos Baziotis

St. Savas Oncology Hospital, Nuclear Medicine Department, Athens, Greece

aAddress correspondence to this author at: St. Savas Oncology Hospital, Nuclear Medicine Department, 171 Alexandras Ave., Athens 115 22, Greece, e-mail azanglis@yahoo.gr

The first 20% of the full text of this article appears below.


To the Editor:

In our RIA laboratory, we serendipitously observed that an unusual number of patients referred from the outpatient endocrinology clinic of the St. Savas Oncology Hospital had parathyroid hormone (PTH) concentrations exceeding the recommended upper reference limit of 6.90 pmol/L (65 ng/L) of our assay (ELSA-PTH, Cisbio International). Further work-up failed to show any evidence for hyperparathyroidism, but these patients were all receiving L-thyroxine for various thyroid problems, and their thyrotropin (TSH) concentrations were very suppressed (<0.4 mIU/L).

To investigate this phenomenon further, we obtained blood samples from all patients on thyroxine therapy (for goiter, hypothyroidism, thyroiditis, or thyroid cancer) referred to our laboratory. As a reference population, healthy blood donors, matched for age and sex and on no medication, were also included in our study. The study was conducted after institutional review board approval, and all participants gave their informed consent. The PTH was assayed in plasma samples obtained in EDTA-containing plastic tubes (Vacutainer®, Beckton Dickinson) and immediately centrifuged (1000g) for . . . [Full Text of this Article]






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.